- Home
- ATRC vs BCAX Comparison
ATRC vs BCAX Comparison
Compare ATRC & BCAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATRC
- BCAX
- Stock Information
- Founded
- ATRC 2000
- BCAX 2018
- Country
- ATRC United States
- BCAX United States
- Employees
- ATRC N/A
- BCAX N/A
- Industry
- ATRC Medical/Dental Instruments
- BCAX
- Sector
- ATRC Health Care
- BCAX
- Exchange
- ATRC Nasdaq
- BCAX NYSE
- Market Cap
- ATRC 1.6B
- BCAX 487.6M
- IPO Year
- ATRC 2005
- BCAX 2024
- Fundamental
- Price
- ATRC $31.00
- BCAX $10.19
- Analyst Decision
- ATRC Strong Buy
- BCAX Strong Buy
- Analyst Count
- ATRC 10
- BCAX 7
- Target Price
- ATRC $49.50
- BCAX $29.17
- AVG Volume (30 Days)
- ATRC 393.5K
- BCAX 671.5K
- Earning Date
- ATRC 07-29-2025
- BCAX 08-16-2025
- Dividend Yield
- ATRC N/A
- BCAX N/A
- EPS Growth
- ATRC N/A
- BCAX N/A
- EPS
- ATRC N/A
- BCAX N/A
- Revenue
- ATRC $480,076,000.00
- BCAX N/A
- Revenue This Year
- ATRC $14.63
- BCAX N/A
- Revenue Next Year
- ATRC $12.62
- BCAX N/A
- P/E Ratio
- ATRC N/A
- BCAX N/A
- Revenue Growth
- ATRC 15.79
- BCAX N/A
- 52 Week Low
- ATRC $20.20
- BCAX $7.80
- 52 Week High
- ATRC $43.11
- BCAX $28.09
- Technical
- Relative Strength Index (RSI)
- ATRC 42.67
- BCAX N/A
- Support Level
- ATRC $30.49
- BCAX N/A
- Resistance Level
- ATRC $32.44
- BCAX N/A
- Average True Range (ATR)
- ATRC 0.93
- BCAX 0.00
- MACD
- ATRC -0.09
- BCAX 0.00
- Stochastic Oscillator
- ATRC 23.12
- BCAX 0.00
About ATRC AtriCure Inc.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
About BCAX BICARA THERAPEUTICS INC
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.